Published in Aliment Pharmacol Ther on May 22, 2012
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine (2014) 0.89
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat (2013) 0.88
IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One (2014) 0.80
Hepatitis C virus in American Indian/Alaskan Native and Aboriginal peoples of North America. Viruses (2012) 0.79
Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases (2015) 0.79
Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus. J Res Med Sci (2014) 0.79
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. Sci Rep (2015) 0.77
An insight into the molecular characteristics of hepatitis C virus for clinicians. Saudi Med J (2016) 0.76
Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis (2015) 0.75
A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med (2015) 0.75
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest (1997) 2.89
Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis. Am J Gastroenterol (1999) 2.11
Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther (2012) 1.55
Editorial: hepatocellular carcinoma--a rare complication of hepatic venous outflow tract obstruction. Aliment Pharmacol Ther (2015) 1.39
Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.34
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther (2013) 1.28
Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat (2005) 1.19
Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos (1999) 1.09
Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg (1998) 1.01
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther (2012) 0.98
Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther (2010) 0.96
Hepatitis B infection in patients with acute liver failure in the United States. Hepatology (2001) 0.93
Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat (2011) 0.90
The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther (2009) 0.89
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat (2013) 0.88
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther (2010) 0.86
What factors determine the severity of hepatitis A-related acute liver failure? J Viral Hepat (2010) 0.84
An update on drug induced liver injury. Minerva Gastroenterol Dietol (2011) 0.83
Vascular complications of liver transplantation: evaluation with gadolinium-enhanced MR angiography. Radiology (1998) 0.80
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. BMC Gastroenterol (2001) 0.80
Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. J Viral Hepat (2014) 0.80
Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant Proc (2005) 0.79
Helicobacter pylori-associated gastric MALT lymphoma in liver transplant recipients. Transplantation (2001) 0.78
Liver transplantation in acute liver failure. Panminerva Med (2003) 0.78
Characteristics of chronic hepatitis B patients who underwent liver biopsies. J Viral Hepat (2010) 0.78
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat (2011) 0.76
Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol (2000) 0.75
Combination therapy for chronic hepatitis B. Hepatology (1997) 0.75
Seropositive abdominal and thoracic donor organs are largely underutilized. Transplant Proc (2010) 0.75
Outcome of liver transplantation for hepatitis B: report of a single center's experience. Liver Transpl (2001) 0.75
Update of the Adult and Pediatric Liver Transplant Program at the University of Michigan. Clin Transpl (1996) 0.75